Asthma Clinical Trial
Official title:
Exhaled Breath Condensate as a Measurement of Airway Inflammation in Children With Asthma
This study will evaluate the usefulness of a new procedure for evaluating asthma in children.
The method measures the pH (a measure of acidity and alkalinity) of exhaled breath condensate
(water vapor created by the lungs). The condensate contains products of the lungs that may be
associated with lung inflammation. Investigators will determine if the pH of the exhaled
breath condensate correlates well with known asthma indicators, such as number of
hospitalizations, school absenteeism, use of rescue medication, and others. Test results will
be compared with findings from healthy normal volunteers. No experimental treatments or
medicines are used in this study. Patients who require treatment for their asthma will
receive standard care with medicines approved by the Food and Drug Administration and used
widely in the United States.
Children with asthma and healthy normal volunteers between 6 and 17 years of age may be
eligible for this study. You must complete the study before your 18th birthday. Candidates
are screened with a medical history and physical examination.
Children with asthma undergo the following tests and procedures over six clinic visits,
including an initial visit and follow-up visits at 4-8 weeks, 3, 6, 9, and 12 months:
- Blood draw in children over 6 years of age. Medications are available to decrease the
pain associated with blood drawing.(initial visit)
- Allergen skin testing: Drops of up to 16 allergens are placed on the arm. The skin under
each drop is scratched and the area is observed for an allergic reaction. (4- 8-week
follow-up visit)
- Expired nitric oxide testing: The child breathes into a balloon to collect a portion of
the gases exhaled form the lungs. This test measures the amount of nitric oxide, which
correlates with bronchial inflammation. (all visits)
- Exhaled breath condensate: The child breathes into a plastic tube surrounded by a cold
metal sleeve for 10 to 15 minutes. The water vapor created by the lungs (the same vapor
that forms when breathing outside on a cold day) is collected and the pH measured. (all
visits)
- Pulmonary (lung) function test: The child blows very hard into a tube attached to a
machine to measure the airflow from the child's lungs. This test measures airflow from
the lungs. (all visits) The children are given small plastic device called a peak flow
meter - a device used to measure lung function - to use at home. Children whose lung
function is less than 80% of the predicted value for their age may be given medicine to
see if their lung function improves.
- Review of the patient's symptoms, sick days, medicines or actions taken to get over the
illness; review of peak flow reports; and review of action plan. (3-, 6-, 9-, and
12-month visits)
Healthy controls will have the expired nitric oxide test, exhaled breath condensate test, and
pulmonary function test at each visit at the initial and over two additional visits scheduled
6 months apart.
The onset of asthma is often during childhood, and when the child is atopic, it is more
likely to persist into adulthood. Diseases such as asthma have a higher prevalence in
childhood; and management that alters the morbidity of allergic disease in children may
impact disease outcomes in future years.
Asthma is the most prevalent chronic disease in childhood and accounts for the highest rate
of hospitalizations in the ages between 0-4 years. Unfortunately, there are few noninvasive
objective measurements of pulmonary health in children. Current techniques include
determination of peak flow, spirometry, and measurement of nitric oxide (NO). Bronchial
inflammation is a central feature of asthma and anti-inflammatory therapy is the mainstay of
treatment. Expired NO (eNO) has been shown to correlate with bronchial inflammation. However,
the collection of NO has only been available in research settings due to the limitations of
collection and analysis. In contrast, exhaled breath condensate (EBC) is easily obtained and
pH analysis technically simple.
Determination of pH in EBC is a novel, non-invasive technique in clinical study as a means to
evaluate the severity of pulmonary inflammation. In the protocol described, we will evaluate
the utility of EBC in the measurement of airway disease in 60 children with asthma and
compare them to 30 healthy cohorts in the same age range. We will determine if EBC pH is
reflective of the degree of morbidity in children by correlating measurements with known
parameters of disease including: 1) number of hospitalizations, 2) absenteeism from school,
3) number of asthma exacerbations, 4) loss of work days (if applicable), 5) extent of rescue
medication usage, 6) spirometry to evaluate obstruction, and 7) NO as a measurement of
inflammation.
Subjects will be evaluated and then categorized based on the National Asthma Education and
Prevention Program (NAEPP) guidelines. We will measure the pH from EBC in children age 6 to
less than 18 years of age and compare findings to clinical data, spirometry, and expired NO.
In this way, we will determine if EBC is a potentially useful non-invasive measurement of
airway disease. It is hoped that measurements of EBC will be helpful in identifying those
children in which the addition of an anti-inflammatory medication is appropriate. We will
also attempt to measure inflammatory mediators to determine if they can be used to assess
inflammation.
This method may also be useful in detecting airway inflammation due to an infectious agent
before a systemic reaction (fever, respiratory distress, or cough) is apparent in children
with various immunodeficiency diseases such as chronic granulomatous disease (CGD), recurrent
respiratory infections without a defined host defect (RIND), or Job's syndrome.
We will recruit 30 healthy control children in the same age range to compare the EBC pH
values in children without allergic or other chronic pulmonary diseases. In addition, we will
recruit 30 children (10 in each group) with CGD, RIND, and Job's to compare exhaled breath
condensate pH and exhaled nitric oxide values to those from children with allergic airway
inflammation to determine if these methods are useful for early diagnosis of infectious
airway inflammation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|